Literature DB >> 26556989

Gut microbiota and host metabolism in liver cirrhosis.

Makoto Usami1, Makoto Miyoshi1, Hayato Yamashita1.   

Abstract

The gut microbiota has the capacity to produce a diverse range of compounds that play a major role in regulating the activity of distal organs and the liver is strategically positioned downstream of the gut. Gut microbiota linked compounds such as short chain fatty acids, bile acids, choline metabolites, indole derivatives, vitamins, polyamines, lipids, neurotransmitters and neuroactive compounds, and hypothalamic-pituitary-adrenal axis hormones have many biological functions. This review focuses on the gut microbiota and host metabolism in liver cirrhosis. Dysbiosis in liver cirrhosis causes serious complications, such as bacteremia and hepatic encephalopathy, accompanied by small intestinal bacterial overgrowth and increased intestinal permeability. Gut dysbiosis in cirrhosis and intervention with probiotics and synbiotics in a clinical setting is reviewed and evaluated. Recent studies have revealed the relationship between gut microbiota and host metabolism in chronic metabolic liver disease, especially, non-alcoholic fatty liver disease, alcoholic liver disease, and with the gut microbiota metabolic interactions in dysbiosis related metabolic diseases such as diabetes and obesity. Recently, our understanding of the relationship between the gut and liver and how this regulates systemic metabolic changes in liver cirrhosis has increased. The serum lipid levels of phospholipids, free fatty acids, polyunsaturated fatty acids, especially, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid have significant correlations with specific fecal flora in liver cirrhosis. Many clinical and experimental reports support the relationship between fatty acid metabolism and gut-microbiota. Various blood metabolome such as cytokines, amino acids, and vitamins are correlated with gut microbiota in probiotics-treated liver cirrhosis patients. The future evaluation of the gut-microbiota-liver metabolic network and the intervention of these relationships using probiotics, synbiotics, and prebiotics, with sufficient nutrition could aid the development of treatments and prevention for liver cirrhosis patients.

Entities:  

Keywords:  Fatty acids; Liver cirrhosis; Metabolism; Microbiota; Probiotics

Mesh:

Year:  2015        PMID: 26556989      PMCID: PMC4631963          DOI: 10.3748/wjg.v21.i41.11597

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  107 in total

Review 1.  The interaction between bacteria and bile.

Authors:  Máire Begley; Cormac G M Gahan; Colin Hill
Journal:  FEMS Microbiol Rev       Date:  2005-09       Impact factor: 16.408

Review 2.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

3.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.

Authors:  Yukihiro Furusawa; Yuuki Obata; Shinji Fukuda; Takaho A Endo; Gaku Nakato; Daisuke Takahashi; Yumiko Nakanishi; Chikako Uetake; Keiko Kato; Tamotsu Kato; Masumi Takahashi; Noriko N Fukuda; Shinnosuke Murakami; Eiji Miyauchi; Shingo Hino; Koji Atarashi; Satoshi Onawa; Yumiko Fujimura; Trevor Lockett; Julie M Clarke; David L Topping; Masaru Tomita; Shohei Hori; Osamu Ohara; Tatsuya Morita; Haruhiko Koseki; Jun Kikuchi; Kenya Honda; Koji Hase; Hiroshi Ohno
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

4.  Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.

Authors:  Nitin Gupta; Ashish Kumar; Praveen Sharma; Vishal Garg; Barjesh C Sharma; Shiv K Sarin
Journal:  Liver Int       Date:  2013-04-21       Impact factor: 5.828

Review 5.  Gut-liver axis in alcoholic liver disease.

Authors:  Gyongyi Szabo
Journal:  Gastroenterology       Date:  2014-11-11       Impact factor: 22.682

6.  The footprints of gut microbial-mammalian co-metabolism.

Authors:  Xiaojiao Zheng; Guoxiang Xie; Aihua Zhao; Linjing Zhao; Chun Yao; Norman H L Chiu; Zhanxiang Zhou; Yuqian Bao; Weiping Jia; Jeremy K Nicholson; Wei Jia
Journal:  J Proteome Res       Date:  2011-10-24       Impact factor: 4.466

7.  Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts.

Authors:  L E M Willemsen; M A Koetsier; S J H van Deventer; E A F van Tol
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Correlation between local monocarboxylate transporter 1 (MCT1) and glucose transporter 1 (GLUT1) densities in the adult rat brain.

Authors:  Martin H Maurer; Martin Canis; Wolfgang Kuschinsky; Roman Duelli
Journal:  Neurosci Lett       Date:  2004-01-23       Impact factor: 3.046

9.  Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.

Authors:  Javier Vaquero; Maria J Monte; Mercedes Dominguez; Jordi Muntané; Jose J G Marin
Journal:  Biochem Pharmacol       Date:  2013-08-06       Impact factor: 5.858

Review 10.  Hepatitis C virus life cycle and lipid metabolism.

Authors:  Costin-Ioan Popescu; Laura Riva; Ovidiu Vlaicu; Rayan Farhat; Yves Rouillé; Jean Dubuisson
Journal:  Biology (Basel)       Date:  2014-12-15
View more
  35 in total

Review 1.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

2.  Gut bacteria may control development of hepatocellular carcinoma.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

3.  Non-hepatic Cancers Independently Predict Liver Decompensation Events.

Authors:  Yuchen Wang; Bashar M Attar; Rohit Agrawal; Ishaan Vohra; Muhammad Zain Farooq; Sheeba Ba Aqeel; Melchor Demetria
Journal:  J Gastrointest Cancer       Date:  2021-06

4.  Integrated omics analysis: the relationship between significantly increased Klebsiella post-hepatectomy and decreased hub-metabolite 3-methyl-2-oxobutanoic acid is associated with induced liver failure.

Authors:  Yu-Chong Peng; Xin-Hua Zhao; Chuan-Fa Zeng; Jing-Xuan Xu; Lu-Nan Qi; Le-Qun Li
Journal:  J Gastrointest Oncol       Date:  2022-02

Review 5.  Emerging Role of Edible Exosomes-Like Nanoparticles (ELNs) as Hepatoprotective Agents.

Authors:  P Debishree Subudhi; Chhagan Bihari; Shiv Kumar Sarin; Sukriti Baweja
Journal:  Nanotheranostics       Date:  2022-06-21

6.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

7.  Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.

Authors:  Dana Tedesco; Manoj Thapa; Chui Yoke Chin; Yong Ge; Minghao Gong; Jing Li; Sanjeev Gumber; Patrick Speck; Elizabeth J Elrod; Eileen M Burd; William H Kitchens; Joseph F Magliocca; Andrew B Adams; David S Weiss; Mansour Mohamadzadeh; Arash Grakoui
Journal:  Gastroenterology       Date:  2018-02-15       Impact factor: 22.682

8.  Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.

Authors:  Zidong Donna Fu; Julia Yue Cui
Journal:  Curr Pharmacol Rep       Date:  2017-03-03

9.  Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach.

Authors:  Xiao Wei; Shan Jiang; Yuye Chen; Xiangna Zhao; Huan Li; Weishi Lin; Boxing Li; Xuesong Wang; Jing Yuan; Yansong Sun
Journal:  BMC Gastroenterol       Date:  2016-10-04       Impact factor: 3.067

Review 10.  Treating the Metabolic Syndrome by Fecal Transplantation-Current Status.

Authors:  Stephen D H Malnick; David Fisher; Marina Somin; Manuela G Neuman
Journal:  Biology (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.